Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05UFP
|
||||
| Former ID |
DNCL003309
|
||||
| Drug Name |
PEG-SN38
|
||||
| Synonyms |
EZN-2208
|
||||
| Drug Type |
Small molecular drug
|
||||
| Company |
Enzon pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C118H122N12O37
|
||||
| Canonical SMILES |
CCC1=C2C=C(C=CC2=NC3=C1CN4C3=CC5=C(C4=O)COC(=O)C5(CC)OC<br />(=O)CNC(=O)COCCOCC(COCC(COCCOCC(=O)NCC(=O)OC6(C7=C(COC6<br />=O)C(=O)N8CC9=C(C8=C7)N=C1C=CC(=CC1=C9CC)O)CC)OCCOCC(=O<br />)NCC(=O)OC1(C2=C(COC1=O)C(=O)N1CC3=C(C1=C2)N=C1C=CC(=CC<br />1=C3CC)O)CC)OCCOCC(=O)NCC(=O)OC1(C2=C(COC1=O)C(=O)N1CC3<br />=C(C1=C2)N=C1C=CC(=CC1=C3CC)O)CC)O
|
||||
| InChI |
1S/C118H122N12O37/c1-9-67-71-33-61(131)17-21-87(71)123-103-75(67)45-127-91(103)37-83-79(107(127)143)53-160-111(147)115(83,13-5)164-99(139)41-119-95(135)57-153-27-25-151-49-65(158-31-29-155-59-97(137)121-43-101(141)166-117(15-7)85-39-93-105-77(47-129(93)109(145)81(85)55-162-113(117)149)69(11-3)73-35-63(133)19-23-89(73)125-105)51-157-52-66(159-32-30-156-60-98(138)122-44-102(142)167-118(16-8)86-40-94-106-78(48-130(94)110(146)82(86)56-163-114(118)150)70(12-4)74-36-64(134)20-24-90(74)126-106)50-152-26-28-154-58-96(136)120-42-100(140)165-116(14-6)84-38-92-104-76(46-128(92)108(144)80(84)54-161-112(116)148)68(10-2)72-34-62(132)18-22-88(72)124-104/h17-24,33-40,65-66,131-134H,9-16,25-32,41-60H2,1-8H3,(H,119,135)(H,120,136)(H,121,137)(H,122,138)/t65?,66?,115-,116-,117-,118-/m0/s1
|
||||
| InChIKey |
CXWRXYDTWCBSJF-DPTNTHPESA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Toposisomerase-1 | Target Info | Inhibitor | [532064] | |
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | DNA replication | ||||
| Pathway Interaction Database | Caspase Cascade in Apoptosis | ||||
| WikiPathways | Integrated Pancreatic Cancer Pathway | ||||
| References | |||||
| Ref 522902 | ClinicalTrials.gov (NCT01036113) A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer. U.S. National Institutes of Health. | ||||
| Ref 532503 | Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer. Cancer. 2013 Dec 15;119(24):4223-30. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.